Embecta is global medical device company focused on providing solutions to improve the health and wellbeing of people living with diabetes. Co. has a portfolio of marketed products, including various of pen needles, syringes and safety devices, which are complemented by its proprietary digital applications. Co.'s pen needles are sterile, single-use, medical devices, designed to be used in conjunction with insulin pens and are used to inject insulin or other diabetes medications. Co. also sells safety pen needles, which include resin injection-molded shields on both ends of the cannula that automatically deploy to help prevent needlestick exposure and injury during injection and disposal.
When researching a stock like Embecta, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from EMBC Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for EMBC stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the EMBC 200 day moving average ("EMBC 200 DMA"), while one of the most popular "shorter look-backs" is the EMBC 50 day moving average ("EMBC 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Embecta. |